Home / Peptide guides / BPC-157 and the FDA interim policy
Is BPC-157 about to be compoundable?
The FDA just sent a peptide policy to the White House. Here's what's actually on the table, who's fighting it, and where BPC-157 stands today.
The short version: not yet. BPC-157 is not FDA-approved and is not on the list compounders can use. A new FDA policy could change that, but it's still under review and nobody outside government has seen it.
The policy: RIN 0910-ZD94
- What: "Interim Access Policy for Compounding Using Certain Peptides," from HHS/FDA, stage: Notice.
- Where it is: received for OMB/OIRA review on Oct 14, 2026, pending review (OIRA EO 12866 review entry, reginfo.gov).
- What's in it: the details aren't public. Reuters reports the filing "does not provide any details of the policy"; the AP, citing two people familiar with it, said it would let compounders make some popular peptides including BPC-157 (as reported by Reuters).
- Status: not published and not in effect.
Where BPC-157 stands today
- Not FDA-approved for any use (our FDA list).
- Not on category 1, the list of bulk substances 503A compounders may use while FDA reviews them (FDA 503A categories).
- FDA lists it among substances nominated, then withdrawn, with safety concerns (FDA).
- The July 2026 advisory vote was non-binding. FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 and five others for the list (FDA meeting page; vote report). Advisers recommended loosening restrictions on six of the seven peptides reviewed (Reuters). FDA hasn't acted on it.
The pushback: Doctors for America
On Oct 16, Doctors for America urged OMB to return the policy to FDA (DFA statement). Their main points, in their words:
- The policy "would let compounding pharmacies sell injectable peptides that have never been shown to be safe, effective, or even reliably identified."
- "In July, FDA's own scientists recommended that none of the seven peptides reviewed be added to the compounding list," and the committee "overrode them on narrow 8–6 votes."
- On BPC-157 evidence, they cite a 2025 HSS Journal systematic review that found 35 animal studies and one small retrospective human report (12 patients with knee pain, 7 reporting relief).
- They want any addition to go through proposed rule, public comment and final rule, with FDA's evidence reviews published.
Who wants it: telehealth
Telehealth company Hims & Hers has said it plans to offer peptides if regulations permit (Reuters). Peptides have also been promoted by HHS Secretary Robert F. Kennedy Jr. (Reuters).
What happens next
OIRA can clear the policy, ask for changes, or send it back. Until FDA publishes something, nothing changes: BPC-157 stays research-only. We'll update this page when OMB acts.
Not FDA-approved; sold for research only. Known risks: not well studied in people (mostly animal studies); FDA cites immunogenicity, impurity and limited-safety-data concerns (FDA). Choose a tested source.
Get the next big peptide study first
New results like this, explained plainly in five minutes, every Friday. Free.
BPC-157 policy FAQ
Can pharmacies compound BPC-157 now?
No. BPC-157 is not on FDA's category 1 list of bulk substances compounders may use while under review (FDA 503A list), and FDA lists it as nominated, then withdrawn, with safety concerns (FDA). The interim policy is not in effect.
What is RIN 0910-ZD94?
It's the tracking number for FDA's "Interim Access Policy for Compounding Using Certain Peptides," received for White House (OMB/OIRA) review on Oct 14, 2026 (OIRA EO 12866 review entry, reginfo.gov). The text hasn't been released.
Is BPC-157 FDA-approved?
No. It isn't an approved drug for any use. See our FDA-approved peptides list.
Not medical advice. Education only. Talk to a licensed clinician about your health.